Psychological well-being declines years before diagnosis of MCI
Aug 20, 2024
The findings were seen specifically for the components of purpose in life and personal growth.
FDA delays decision on new Alzheimer’s drug
Mar 08, 2024
Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Levetiracetam well-tolerated for Alzheimer’s disease
Oct 01, 2021
It does not improve primary outcome but did improve performance on certain cognitive tasks in those with epileptiform activity.
Higher habitual coffee intake may slow cognitive decline
Nov 30, 2021
Higher baseline coffee consumption also was linked to slower Aβ-amyloid accumulation during a 126-month study period, as shown on brain MRI scans.
Hypertension, type 2 diabetes contribute to brain changes in Puerto Rican seniors
Apr 01, 2022
A high prevalence of hypertension and type 2 diabetes was seen among the Puerto Rican cohort; those with both have deteriorating patterns in major white matter tracts.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...